Inhibrx Biosciences, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45720N1037
USD
101.32
-9.25 (-8.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Inhibrx Biosciences, Inc.

Why is Inhibrx Biosciences, Inc. ?

1
Positive results in Sep 25
  • NET SALES(HY) At USD 1.3 MM has Grown at 1,200%
  • NET PROFIT(HY) Higher at USD -63.91 MM
  • RAW MATERIAL COST(Y) Fallen by 0% (YoY)
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 307.75%, its profits have fallen by -38%
3
Rising Promoter Confidence
  • Promoters have increased their stake in the company by 0.81% over the previous quarter and currently hold 11.85% of the company
  • Promoters increasing their stake is a sign of high confidence in the future of the business
4
Market Beating Performance
  • The stock has generated a return of 307.75% in the last 1 year, much higher than market (S&P 500) returns of 11.87%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-69.80%
EBIT Growth (5y)
-175.30%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
89.13%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
27.35
EV to EBIT
-6.21
EV to EBITDA
-6.32
EV to Capital Employed
-67.86
EV to Sales
683.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-421.09%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -131.92 MM

NET PROFIT(HY)

Higher at USD -66.28 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 6.5 times

-12What is not working for the Company
ROCE(HY)

Lowest at -354.69%

DEBT-EQUITY RATIO (HY)

Highest at -91.47 %

INTEREST(Q)

Highest at USD 3.51 MM

Here's what is working for Inhibrx Biosciences, Inc.

Operating Cash Flow
Highest at USD -131.92 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -66.28 MM
than preceding 12 month period ended Mar 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debtors Turnover Ratio
Highest at 6.5 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Inhibrx Biosciences, Inc.

Interest
Highest at USD 3.51 MM
in the last five periods and Increased by 10.17% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at -91.47 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio